




Edition: BP 2025 (Ph. Eur. 11.6 update)

## Leucine



### [General Notices](#)

(Ph. Eur. monograph 0771)



$C_6H_{13}NO_2$  131.2 61-90-5

### Action and use

Amino acid.

Ph Eur

## DEFINITION

(2S)-2-Amino-4-methylpentanoic acid.

Product of fermentation or of protein hydrolysis.

### Content

98.5 per cent to 101.0 per cent (dried substance).

## CHARACTERS

### Appearance

White or almost white, crystalline powder or shiny flakes.

### Solubility

Sparingly soluble in water, practically insoluble in ethanol (96 per cent). It dissolves in dilute mineral acids and in dilute solutions of alkali hydroxides.

## IDENTIFICATION

*First identification:* A, B.

*Second identification:* A, C.

A. Specific optical rotation (see Tests).

B. Infrared absorption spectrophotometry ([2.2.24](#))

*Comparison* [leucine CRS](#).

C. Thin-layer chromatography ([2.2.27](#)).

*Test solution* Dissolve 10 mg of the substance to be examined in a 10.3 g/L solution of [hydrochloric acid R](#) and dilute to 50 mL with the same solution.

*Reference solution* Dissolve 10 mg of [leucine CRS](#) in a 10.3 g/L solution of [hydrochloric acid R](#) and dilute to 50 mL with the same solution.

*Plate* [TLC silica gel plate R](#).

*Mobile phase* [glacial acetic acid R](#), [water R](#), [butanol R](#) (20:20:60 V/V/V).

*Application* 5 µL.

*Development* Over 2/3 of the plate.

*Drying* In air.

*Detection* Spray with [ninhydrin solution R](#) and heat at 105 °C for 15 min.

*Results* The principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

## TESTS

### Appearance of solution

The solution is clear ([2.2.1](#)) and not more intensely coloured than reference solution BY<sub>6</sub> ([2.2.2, Method II](#)).

Dissolve 0.5 g in a 103 g/L solution of [hydrochloric acid R](#) and dilute to 10 mL with the same solution.

### [Specific optical rotation](#) ([2.2.7](#))

+ 14.5 to + 16.5 (dried substance).

Dissolve 1.00 g in [hydrochloric acid R1](#) and dilute to 25.0 mL with the same acid.

### Ninhydrin-positive substances

Amino acid analysis ([2.2.56](#)). For analysis, use Method 1.

The concentrations of the test solutions and the reference solutions may be adapted according to the sensitivity of the equipment used. The concentrations of all solutions are adjusted so that the system

suitability requirements described in general chapter [2.2.46](#) are fulfilled, keeping the ratios of concentrations between all solutions as described.

**Solution A** [dilute hydrochloric acid R1](#) or a sample preparation buffer suitable for the apparatus used.

**Test solution (a)** Dissolve 30.0 mg of the substance to be examined in solution A and dilute to 50.0 mL with solution A.

**Test solution (b)** Dilute 1.0 mL of test solution (a) to 25.0 mL with solution A.

**Reference solution (a)** Dilute 1.0 mL of test solution (a) to 100.0 mL with solution A. Dilute 2.0 mL of this solution to 10.0 mL with solution A.

**Reference solution (b)** Dissolve 30.0 mg of [isoleucine R](#) (impurity A) in solution A and dilute to 100.0 mL with solution A. Dilute 1.0 mL of the solution to 250.0 mL with solution A. Dilute 1.0 mL of this solution to 10.0 mL with solution A.

**Reference solution (c)** Dissolve 30.0 mg of [proline R](#) in solution A and dilute to 100.0 mL with solution A. Dilute 1.0 mL of the solution to 250.0 mL with solution A.

**Reference solution (d)** Dilute 6.0 mL of [ammonium standard solution \(100 ppm NH<sub>4</sub>\) R](#) to 50.0 mL with solution A. Dilute 1.0 mL of this solution to 100.0 mL with solution A.

**Reference solution (e)** Dissolve 30 mg of [isoleucine R](#) (impurity A) and 30 mg of [leucine R](#) in solution A and dilute to 50.0 mL with solution A. Dilute 1.0 mL of the solution to 200.0 mL with solution A.

**Blank solution** Solution A.

Inject suitable, equal amounts of the test solutions, blank solution and reference solutions (a), (b), (c) and (e) into the amino acid analyser. Run a program suitable for the determination of physiological amino acids.

**System suitability** Reference solution (e):

- [resolution](#): minimum 1.5 between the peaks due to impurity A and leucine.

**Calculation of percentage contents:**

- for impurity A in test solution (b), use the concentration of impurity A in reference solution (b);
- for any ninhydrin-positive substance detected at 570 nm in test solution (a), use the concentration of leucine in reference solution (a);
- for any ninhydrin-positive substance detected at 440 nm in test solution (a), use the concentration of proline in reference solution (c); if a peak is above the reporting threshold at both wavelengths, use the result obtained at 570 nm for quantification.

**Limits:**

- *impurity A at 570 nm*: maximum 0.8 per cent;
- *any ninhydrin-positive substance*: for each impurity, maximum 0.2 per cent;
- *total*: maximum 1.0 per cent;
- *reporting threshold*: 0.05 per cent.

The thresholds indicated under Related substances (Table 2034.-1) in the general monograph [Substances for pharmaceutical use \(2034\)](#) do not apply.

#### **Chlorides** ([2.4.4](#))

Maximum 200 ppm.

Dissolve 0.25 g in [water R](#) and dilute to 15 mL with the same solvent.

### **Sulfates** ([2.4.13](#))

Maximum 300 ppm.

Dissolve 0.5 g in 3 mL of [dilute hydrochloric acid R](#) and dilute to 15 mL with [distilled water R](#).

### **Ammonium**

Amino acid analysis ([2.2.56](#)) as described in the test for ninhydrin-positive substances with the following modifications.

*Injection* Test solution (a), reference solution (d) and blank solution.

*Limit:*

— *ammonium at 570 nm*: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (d) (0.02 per cent), taking into account the peak due to ammonium in the chromatogram obtained with the blank solution.

### **Iron** ([2.4.9](#))

Maximum 10 ppm.

In a separating funnel, dissolve 1.0 g in 10 mL of [dilute hydrochloric acid R](#). Shake with 3 quantities, each of 10 mL, of [methyl isobutyl ketone R1](#), shaking for 3 min each time. To the combined organic layers add 10 mL of [water R](#) and shake for 3 min. Use the aqueous layer.

### **Loss on drying** ([2.2.32](#))

Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

### **Sulfated ash** ([2.4.14](#))

Maximum 0.1 per cent, determined on 1.0 g.

## **ASSAY**

Dissolve 0.100 g in 3 mL of [anhydrous formic acid R](#). Add 30 mL of [anhydrous acetic acid R](#). Titrate with [0.1 M perchloric acid](#), determining the end-point potentiometrically ([2.2.20](#)).


1 mL of [0.1 M perchloric acid](#) is equivalent to 13.12 mg of  $C_6H_{13}NO_2$ .

## **STORAGE**


Protected from light.

## **IMPURITIES**


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities. It is therefore not necessary to identify these impurities for demonstration of compliance. See also [5.10. Control of impurities in substances for pharmaceutical use](#)) B, C, D, E.




A. (2S,3S)-2-amino-3-methylpentanoic acid (isoleucine),




B. (2S)-2-amino-4-(methylsulfanyl)butanoic acid (methionine),



C. (2S)-2-amino-3-phenylpropanoic acid (phenylalanine),



D. (2S)-2-amino-5-methylhexanoic acid (5-methyl-norleucine),



E. (2S)-2-amino-3-methylbutanoic acid (valine).